A new committee has been established by the European Medicines Agency (EMA), called the Scientific Coordination Board. According to a press-release, the group aims to ensure “sufficient coordination between the committees, so that the standards they set for the development of medicines are consistent across the whole product life-cycle, for increased robustness and predictability of benefit-risk assessment.”